What kinds of cancer can ZIRABEV help to treat?

INDICATIONS

Metastatic Colorectal Cancer (mCRC)

ZIRABEV is approved to treat mCRC for:

  • First- or second-line treatment in combination with intravenous fluorouracil-based chemotherapy
  • Second-line treatment when used with fluoropyrimidine-based (combined with irinotecan or oxaliplatin) chemotherapy after cancer progresses following a first-line treatment that includes a bevacizumab product

ZIRABEV is not approved for use after the primary treatment of colon cancer that has not spread to other parts of the body.

Non-Small Cell Lung Cancer (NSCLC)

ZIRABEV, in combination with carboplatin and paclitaxel, is approved to treat advanced non-squamous NSCLC in people who have not received chemotherapy for their advanced disease.

Recurrent Glioblastoma (GBM)

ZIRABEV is approved to treat GBM in adult patients whose cancer has progressed after prior treatment (recurrent or rGBM).

Metastatic Renal Cell Carcinoma (mRCC)

ZIRABEV, used with interferon alfa, is approved to treat mRCC.

Advanced Cervical Cancer (CC)

ZIRABEV, in combination with paclitaxel and cisplatin or paclitaxel and topotecan, is approved to treat persistent, recurrent, or metastatic cancer of the cervix.

Ovarian Cancer (OC)

ZIRABEV is approved to treat epithelial ovarian, fallopian tube, or primary peritoneal cancer:

  • In combination with carboplatin and paclitaxel, followed by ZIRABEV alone, for the treatment of patients with advanced (stage III or IV) disease following initial surgery
  • In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan, for platinum-resistant recurrent disease in women who received no more than 2 prior chemotherapy treatments
  • Either in combination with carboplatin and paclitaxel or with carboplatin and gemcitabine, followed by ZIRABEV alone, for patients with platinum-sensitive recurrent disease